下一个

自动播放

Emerging novel agents for the treatment of mastocytosis

1 意见 • 07/09/23
分享
嵌入
administrator
administrator
订户
0

Tracy George, MD, ARUP Laboratories, University of Utah, Salt Lake City, UT comments on the movement from broad, cladribine-based regimens to novel, targeted tyrosine kinase inhibitors (TKIs) such as avapritinib, for the treatment of systemic mastocytosis. Dr George also comments on the future development of antibody-based therapies, emphasizing the importance of more selective agents with fewer side effects. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

显示更多
0 注释 sort 排序方式
脸书评论

下一个

自动播放